Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Public ClinicalTrials.gov record NCT01085201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Study identification
- NCT ID
- NCT01085201
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Interventions
- Lexiscan Drug
Drug
Eligibility (public fields only)
- Age range
- 10 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2010
- Primary completion
- Jan 31, 2013
- Completion
- Feb 28, 2013
- Last update posted
- Mar 6, 2014
2010 – 2013
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Howard University Hospital | Washington D.C. | District of Columbia | — | — |
| Johns Hopkins University | Baltimore | Maryland | — | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Childrens Hospital Boston | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Washington University | St Louis | Missouri | — | — |
| Blood Center of Wisconsin | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01085201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2014 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01085201 live on ClinicalTrials.gov.